Related Experiment Video
Updated: Sep 15, 2025

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226
Published on: May 10, 2022
ILC2s in cancer: good, bad, or stay tuned?
Sara Asif1, Megan Kinzel2, Barbara Vanderhyden3
1Cancer Research Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Center for Infection, Immunity and Inflammation, University of Ottawa, Ottawa, ON, Canada; Department of Biochemistry, Microbiology, and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
Abstract:
Group 2 innate lymphoid cells (ILC2s) are emerging players in tumor immunity. ILC2 heterogeneity confers tissue-specific outcomes, with sometimes opposing effects on the prognosis and progression of various cancers. The role of ILC2s in breast and ovarian cancer is an active area of investigation, with research aimed at leveraging these cells to enhance immunotherapy.
Related Concept Videos
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer Cell Migration through Invadopodia
lncRNA - Long Non-coding RNAs
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Selectins

